

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 8 August 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated						
a)	Name of the Board member/Executive/Associated Person	Andreas Fibig				
2 Reason for the notification						
a)	Position/status	Member of the Board of Directors				
b)	Initial notification/Amendment	Initial notification				
3 Details of the issuer						
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4 Details of the transaction(s)						
a)	Description of the financial instrument, type of instrument, Identification code	ADRs NVO				
b)	Nature of the transaction	Purchase of ADRs				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td> </td> <td> </td> </tr> </tbody> </table>	Price(s)	Volume(s)		
Price(s)	Volume(s)					

		DKK 731.87	249 ADRs
		DKK 732.08	0.399 ADRs
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	249.399 ADRs	DKK 731.87
e)	Date of the transaction	2022-08-03	
f)	Place of the transaction	New York Stock Exchange	

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), and [YouTube](#).

Further information

Media:

Ambre Brown Morley	+45 3079 9289	abmo@novonordisk.com
Natalia Salomao Abrahao (US)	+1 848 304 1027	niaa@novonordisk.com

Investors:

Daniel Muusmann Bohsen	+45 3075 2175	dabo@novonordisk.com
Ann Søndermølle Rendbæk	+45 3075 2253	arnd@novonordisk.com
David Heiberg Landsted	+45 3077 6915	dhel@novonordisk.com
Jacob Martin Wiborg Rode	+45 3075 5956	jrde@novonordisk.com
Mark Joseph Root (US)	+1 848 213 3219	mjhr@novonordisk.com